Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RBP4 | P02753 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22791893 | 0.84 | ALDH1A1 (0.41) | CA2ALDH1A1TDP1MAPTL3MBTL1 | |
| SCHEMBL15357740 | 0.77 | MGLL (0.36) | CA2ALDH1A1TSHRMAPTNPSR1 | |
| SCHEMBL783006 | 0.77 | ALDH1A1 (0.39) | CA2ALDH1A1TSHRTDP1MAPT | |
| SCHEMBL19000959 | 0.76 | CA2 (0.35) | CA2ALDH1A1TSHRTDP1GABRA1 | |
| SCHEMBL23029063 | 0.75 | CA2 (0.37) | CA2ALDH1A1TSHRTDP1MAPT | |
| SCHEMBL13036904 | 0.75 | CA2 (0.46) | CA2ALDH1A1TSHRTDP1RBP4 | |
| SCHEMBL13036905 | 0.75 | HDAC4 (0.41) | CA2ALDH1A1TSHRTDP1MAPT | |
| SCHEMBL12563132 | 0.75 | MEN1 (0.35) | ALDH1A1TSHRMAPT | |
| SCHEMBL16812507 | 0.75 | GAA (0.34) | CA2ALDH1A1TSHRMAPT | |
| SCHEMBL9965511 | 0.73 | MGLL (0.41) | ALDH1A1TSHRMAPTGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-03-08 | — | — | US | disclosed |
| US-9790229-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170210728-A1 | Cannabinergic Nitrate Esters And Related Analogs | NORTHEASTERN UNIVERSITY | 2017-07-27 | — | — | US | disclosed |
| US-9580400-B2 | Cannabinergic nitrate esters and related analogs | NORTHEASTERN UNIVERSITY (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160376281-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-12-29 | — | — | US | disclosed |
| US-9428542-B2 | Lupane triterpenoid derivatives and pharmaceutical use thereof | JIANGXI QINGFENG PHARMACEUTICAL INC. (CN) | 2016-08-30 | — | — | US | disclosed |
| US-9249146-B2 | Bruton'S tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20160002195-A1 | CANNABINERGIC NITRATE ESTERS AND RELATED ANALOGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-07 | — | — | US | disclosed |
| US-20150011517-A1 | LUPANE TRITERPENOID DERIVATIVES AND PHARMACEUTICAL USE THEREOF | JIANGXI QINGFENG PHARMACEUTICAL INC. (CN) | 2015-01-08 | — | — | US | disclosed |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-10-16 | — | — | US | disclosed |
| US-8785440-B2 | Bruton's tyrosine kinase inhibitors | BIOGEN IDEC MA, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376281-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | CA2 2659/4885ALDH1A1 4783/4885TSHR 3612/4885 |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | CA2 2659/4885ALDH1A1 4783/4885TSHR 3612/4885 |
| US-20150011517-A1 | LUPANE TRITERPENOID DERIVATIVES AND PHARMACEUTICAL USE THEREOF | LSS, FURIN, CYP51A1 | CA2 4516/4885ALDH1A1 4162/4885TSHR 3693/4885 |
| US-20160002195-A1 | CANNABINERGIC NITRATE ESTERS AND RELATED ANALOGS | CNR2, CNR1, CHRNB3 | CA2 1854/4885ALDH1A1 1850/4885TSHR 2943/4885 |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | ADORA2A, ADORA2B, ADORA3 | CA2 1707/4885ALDH1A1 616/4885TSHR 510/4885 |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | CA2 2659/4885ALDH1A1 4783/4885TSHR 3612/4885 |
| US-20170210728-A1 | Cannabinergic Nitrate Esters And Related Analogs | CNR2, CNR1, CHRNB3 | CA2 1854/4885ALDH1A1 1850/4885TSHR 2943/4885 |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | CA2 2659/4885ALDH1A1 4783/4885TSHR 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.